Sequana Medical NV (Euronext Brussels: SEQUA), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, today announces the presentation of the positive results from the first-in-human single dose DSR proof-of-concept study for volume overload due to heart failure. The investigator-initiated study was conducted by Dr. Jeffrey Testani of Yale University. The study demonstrated that single dose DSR therapy in humans was safe and well-tolerated and resulted in a clinically relevant removal of sodium with consistent results between treated patients.
A key problem in treating patients with volume overload is that the removal of fluid without the removal of the associated sodium only results in a temporary benefit. Sequana Medical’s innovative DSR therapy removes the sodium and then the body eliminates the associated fluid to restore the sodium concentration, resulting in sustained fluid removal. Data from this study demonstrate that DSR can result in the removal of large quantities of sodium and fluid in a safe and tolerable manner. This underscores the potential of Sequana Medical’s alfapump DSR to deliver a new and convenient treatment option for patients with volume overload due to heart failure.
The results have been presented during the late-breaking abstract session at the Heart Failure 2019 congress in Athens, Greece, today at 08:30 CEST (09:30 local time in Athens), by Dr. Jeffrey Testani, Associate Professor and Director of Heart Failure Research at Yale University. The abstract and presentation are available on the Sequana Medical website.